NCT04130542View on ClinicalTrials.gov

Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

276

Participants

Timeline

Start Date

October 31, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Cancer
Interventions
BIOLOGICAL

LVGN6051

IV infusion once every 3 weeks (Q3W).

BIOLOGICAL

KEYTRUDA® (pembrolizumab)

IV infusion once every 3 weeks (Q3W).

Trial Locations (7)

10016

NYU Langone Health, New York

21205

The Johns Hopkins University, Baltimore

47905

Verdi Oncology Research, Lafayette

68130

Nebraska Cancer Specialist, Omaha

92868

University of California Irvine Health, Orange

94115

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco

77030-3722

MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Lyvgen Biopharma Holdings Limited

INDUSTRY